1. Home
  2. CXAI vs CALC Comparison

CXAI vs CALC Comparison

Compare CXAI & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CXApp Inc.

CXAI

CXApp Inc.

N/A

Current Price

$0.22

Market Cap

9.5M

Sector

Technology

ML Signal

N/A

Logo CalciMedica Inc.

CALC

CalciMedica Inc.

N/A

Current Price

$0.61

Market Cap

88.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CXAI
CALC
Founded
N/A
2011
Country
United States
United States
Employees
41
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.5M
88.3M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
CXAI
CALC
Price
$0.22
$0.61
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
10.4M
427.7K
Earning Date
03-20-2026
03-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$70.21
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.16
$0.46
52 Week High
$1.49
$7.20

Technical Indicators

Market Signals
Indicator
CXAI
CALC
Relative Strength Index (RSI) 44.43 32.94
Support Level $0.16 $0.49
Resistance Level $0.25 $0.79
Average True Range (ATR) 0.04 0.08
MACD -0.00 0.06
Stochastic Oscillator 19.66 10.46

Price Performance

Historical Comparison
CXAI
CALC

About CXAI CXApp Inc.

CXApp Inc is a provider of AI-powered employee experience solutions, delivering enterprise-grade software that enhances workplace engagement, productivity, and operational efficiency. The company's flagship product, the CXAI Platform, provides a comprehensive suite of tools designed to empower employees and enable organizations to create smarter workplaces. The product's key components include CXAI Apps, CXAI BTS, and CXAI-VU. The company generates the majority of its revenue from Licenses.

About CALC CalciMedica Inc.

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.

Share on Social Networks: